Clinical trials: Relapsed
Dandruff
Evaluation of the Efficacy of SeS2 Shampoo on Subjects Having Dandruff
A shampoo containing SeS2 was evaluated versus placebo on healthy subjects suffering from dandruff in order to assess clinical benefits and its impact on fungal and bacterial scalp microbiota.
- Trial name
- NCT05506592
- Testing
- dermatological product
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- L'Oreal
Chronic Lymphoid Leukemia, Lymphoid Malignancies
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
The Phase 1 portion of the study evaluated the pharmacokinetic profile and safety of ABT-263 with the objective of defining the dose limiting toxicity and maximum tolerated dose in subjects with lymphoid malignancies.
- Conditions
- Chronic Lymphoid Leukemia, Lymphoid Malignancies, Non-Hodgkin's Lymphoma, Follicular Lymphoma
- Trial name
- NCT00406809
- Testing
- ABT-263
- Where
- 12 sites in United States, Canada
- Volunteers
- 81 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Lymphomas
CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
Currently, a majority of lymphomas cannot be cured by standard chemo-radiotherapy. Cluster of differentiation antigen 30 (CD30) is expressed in many lymphoma subtypes, such as Hodgkin lymphoma (HL) and anaplastic large cell…
- Trial name
- NCT02274584
- Testing
- Anti-CD30 CAR T cells
- Where
- 2 sites in United States, China
- Volunteers
- 20 people
- Sponsor
- Peking University
Leukemia, Myelodysplastic Syndromes
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00077558
- Testing
- fludarabine phosphate, triapine
- Where
- 4 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Relapsing Remitting Multiple Sclerosis
Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
The purpose of this study is to explore immunomodulatory and immunosuppressive mechanisms of action of fingolimod in patients with Relapsing remitting multiple Sclerosis to collect data on biomarkers after initiation of…
- Trial name
- BiobankII (NCT01755871)
- Testing
- Fingolimod
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed).
- Trial name
- NCT04546399
- Testing
- 3-Dimensional Conformal Radiation Therapy, Asparaginase Erwinia chrysanthemi, Biospecimen Collection
- Where
- 227 sites in United States, Australia and 2 more
- Volunteers
- 461 people
- Sponsor
- National Cancer Institute (NCI)
Psychosis
Mindfulness Intervention and Relapse in Psychosis
Practicing mindfulness is popular and well-accepted for its benefits in improving mental and physical health. In particular, its benefits in promoting resilience to stress and well-being have been shown in studies involving…
- Trial name
- NCT04060498
- Testing
- Mindfulness intervention, Psychoeducation intervention
- Where
- Hong Kong
- Volunteers
- 152 people
- Sponsor
- The University of Hong Kong
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Trial name
- NCT07526493
- Testing
- Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Tongji Hospital
Peripheral T-Cell Lymphoma
Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
The main purpose of this study is to test if brentuximab vedotin has an effect on cancer in patients with a certain type of large B-cell lymphoma.
- Trial name
- NCT01841021
- Testing
- Brentuximab vedotin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Healthy Volunteers, Relapsed Multiple Myeloma
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Part A: The purpose of Part A of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.
- Conditions
- Healthy Volunteers, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07342114
- Testing
- RO7875913, Cevostamab
- Where
- New Zealand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Multiple Myeloma
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG2575 monotherapy or in combination with lenalidomide (R) and dexamethasone (d) in patients with…
- Trial name
- NCT04674514
- Testing
- APG-2575, Rd
- Where
- 12 sites in China
- Volunteers
- 48 people
- Sponsor
- Ascentage Pharma Group Inc.
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
- Trial name
- NCT00435916
- Testing
- SGN-40
- Where
- 14 sites in United States
- Volunteers
- 46 people
- Sponsor
- Seagen Inc.
Acute Myeloid Leukemia
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML).
- Trial name
- NCT02014558
- Testing
- Gilteritinib, Voriconazole, Midazolam
- Where
- 26 sites in United States, Germany and 1 more
- Volunteers
- 265 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Large B-Cell Diffuse Lymphoma
Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma
The purpose of this study is to determine the safety and tolerability of adding oral azacitidine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.
- Trial name
- NCT03450343
- Testing
- Oral azacitidine, R-ICE
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical University of South Carolina
Multiple Sclerosis
Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects
Some of the most common side effects of the multiple sclerosis drug Plegridy (pegylated interferon beta-1a) include flu-like symptoms and injection site reactions.
- Trial name
- NCT03424733
- Testing
- Plegridy, Prednisone, Tylenol Pill
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Holy Name Medical Center, Inc.
Solid Tumors
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT04774952
- Testing
- RMC-5552
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Revolution Medicines, Inc.
Non-Hodgkin Lymphoma
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma…
- Trial name
- SUNMO (NCT05171647)
- Testing
- Mosunetuzumab, Polatuzumab vedotin, Tocilizumab
- Where
- 50 sites in United States, Argentina and 11 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
This study evaluates the efficacy and safety of penpulimab plus lenalidomide, rituximab, gemcitabine and oxaliplatin (R2-GemOx) in patients with relapsed/refractory diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT05186558
- Testing
- penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin
- Where
- 4 sites in China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Prostate Cancer
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
The proposed clinical trial will study the effects of 12 months of therapy with ARN-509 alone, or in combination with an LHRH agonist (LHRHa), each compared with LHRHa alone, in men with a rapidly rising serum PSA after prior…
- Trial name
- NCT01790126
- Testing
- ARN-509, LHRH Agonist
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Alcohol Dependence
The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients
Background: Interactive and mobile technology to manage alcohol use problem potentially provide continuing care by offering emotional and instrumental support anywhere and in time, but the effectiveness for maintaining abstinence…
- Trial name
- NCT02385643
- Testing
- SmartPhone Support System
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Ming-Chyi Huang
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.